Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the potential link between contact allergy and frontal fibrosing alopecia, noting the presence of implicated allergens in current literature, but reports no new clinical findings.

In this study, researchers identified a temperature-sensitive mutation in the FERONIA gene of plants that prevents root hair formation at elevated temperatures, highlighting its role in maintaining root hair growth and response to plant hormones.

This study in Morocco found that all women with frontal fibrosing alopecia presented frontotemporal hairline recession, with trichoscopic features such as perifollicular erythema and follicular hyperkeratosis being indicative of the condition, and suggested a potential link between cosmetic products or emotional factors and the disease.

This review discusses frontal fibrosing alopecia, noting its frequent misdiagnosis and highlighting the need for larger studies to better understand its epidemiology, causes, and treatment options; it reports no new clinical findings.

This case report describes a 50-year-old woman with frontal fibrosing alopecia who showed no improvement despite multiple treatments, including intralesional triamcinolone and topical glucocorticoids.

This study found that trichoscopy can confirm the diagnosis and assess the clinical severity of female androgenetic alopecia, correlating specific features with different severity grades.

This study found that oral tofacitinib led to variable hair regrowth in patients with resistant alopecia areata, implying that longer treatment durations may be needed to fully assess its effectiveness.

In this retrospective study, tofacitinib showed promise as a treatment for alopecia areata, with 46.5% of patients experiencing a very good response and minimal adverse effects, suggesting it could be a primary option for moderate to severe cases.

This study found that both tofacitinib and methotrexate effectively reduced hair loss and psychological distress in patients with moderate-to-severe alopecia areata, but tofacitinib showed much greater efficacy. Both treatments had similar safety profiles, with no serious adverse effects reported.

This study introduces an extended approach to the Bonferroni procedure that accounts for correlations among endpoints, aiming to improve test power while maintaining strong control of the family-wise type I error rate in clinical trials.

This study investigated a unique frontal fibrosing alopecia-like presentation of alopecia areata, finding that patients experienced an insidious, chronic course with limited scalp hair regrowth, and showed a lower response to systemic corticosteroids compared to patchy alopecia areata.

Certain drugs and supplements may contribute to hair loss in the frontal hairline in older women.

This study suggests that frontal fibrosing alopecia is a highly inflammatory disease involving TH1 and JAK-STAT pathways, without reduced hair keratins, highlighting JAK-STAT signaling as a potential therapeutic target.

This report presents a case of a patient developing new multiple sclerosis while using tofacitinib for alopecia areata, noting no new comprehensive research findings.

This article discusses the potential of oral tofacitinib as a treatment for atopic dermatitis, alopecia areata, and vitiligo, without presenting new clinical results.

This study found a high concordance between subject-reported and clinician-reported Fitzpatrick Skin Phototypes, but 14% of subjects misjudged their skin type, often overestimating it.

This case study documented a 36-year-old woman with postpartum-onset frontal fibrosing alopecia who showed significant improvement in hair regrowth after early combination therapy with dutasteride, tofacitinib, and intralesional triamcinolone acetonide, suggesting potential benefits of multimodal treatment in this typically irreversible condition.

In this pilot study, both tofacitinib and methotrexate improved alopecia areata outcomes, but tofacitinib showed greater efficacy in achieving significant SALT score improvement after 6 months, although the difference was not statistically significant.

This study found that intermittent treatment with FTI lonafarnib and sulforaphane may be a promising therapeutic approach for children with Hutchinson-Gilford progeria syndrome, as it improved the cellular phenotype.

In this case report, a novel missense mutation c.1360G>C (p.Ala454Pro) in the MBTPS2 gene was identified in a boy with typical IFAP syndrome and severe atopic features, although no phenotype/genotype correlation was established.

Frontal fibrosing alopecia can affect men's beards and leads to permanent hair loss.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

In this report, a 14-year-old female with stubborn alopecia areata was successfully treated with oral tofacitinib, indicating its potential effectiveness for severe cases.

This letter to the editor describes a case of postcast hypertrichosis in a patient with frontal fibrosing alopecia and reports no new research findings.

This study found that tofacitinib may be effective in treating various pediatric rheumatic diseases, particularly juvenile idiopathic arthritis, although some patients did not respond, and side effects were observed.

In this clinical experience, treating frontal fibrosing alopecia with oral finasteride, hydroxychloroquine, tacrolimus, and excimer laser was associated with optimal results in patients with active inflammation.

This study reports a case of frontal fibrosing alopecia associated with hepatitis C treatment involving interferon and ribavirin.

This study revealed distinct cellular and transcriptomic differences among various subtypes of cutaneous T-cell lymphoma, particularly highlighting characteristics unique to folliculotropic mycosis fungoides.

This case report describes a 39-year-old woman whose dermatomyositis-systemic lupus erythematosus overlap syndrome symptoms resolved after switching to tofacitinib.

This study in mice suggests that defects in hair follicles with mesenchymal TSC2 disruption may result from an impaired TGFβ1 response, indicating a potential novel treatment approach for tuberous sclerosis complex.